Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) promotes apoptosis of
cancer cells by both IGF-dependent and IGF-independent mechanisms. In vitro phosphorylation of
IGFBP-3 by
DNA-dependent protein kinase (
DNA-PK) has been reported but with unknown functional relevance. Using a chemical inhibitor for
DNA-PK in
prostate cancer cells and a paired system of
glioblastoma cell lines that either lack or express
DNA-PK, we show that the apoptosis-promoting and growth-inhibitory actions of
IGFBP-3 are completely abrogated in the absence of catalytically active
DNA-PK. In the absence of
DNA-PK activity,
IGFBP-3 has reduced nuclear accumulation and is unable to bind its nuclear binding partner
retinoid X receptor (RXR) alpha. We assessed the importance of the three potential
DNA-PK phosphorylation sites in
IGFBP-3 using PCR-based site-directed mutagenesis. When transfected into 22RV1 cells, IGFBP-3-S165A and IGFBP-3-T170A functioned in an identical manner to wild-type
IGFBP-3 to induce apoptosis. In contrast, IGFBP-3-S156A was unable to promote apoptosis and exhibited reduced nuclear accumulation, suggesting a key role for
DNA-PK-dependent phosphorylation in the regulation of
IGFBP-3 action. These studies reveal a novel regulatory mechanism for the actions of
IGFBP-3 in
prostate cancer and show phosphorylation of Ser(156) to be functionally critical in its apoptosis-inducing actions.